AI-Empowered Bionovel Discovery
We generate differential bionovels with integrated AI/Bio platforms
Vibrant Therapeutics was founded in 2019. Since incorporation, our scientists have been developing incredible cutting-edge technologies integrating antibody discovery, protein engineering, immunology, oncology, structural biology, bioinformatics, and Artificial Intelligence/Machine Learning/Deep Learning. Our investigational biotherapeutics have the potential to save millions of patients with life-threatening diseases. We currently focus on discovery and development of oncology therapeutics.
Our Bionovel Pipeline
Our Research
We analyze protein structures and profiles to discover the patterns by which nature encodes function. We can utilize those identified patterns to generate bionovels with specific therapeutic functions and ideal properties.
We leverage our proprietary computational and biological technologies to create a One Stop R&D (Research and Development) platform, which is called BumbleBee. It facilitates R&D process of innovative bionovels and allows for significant improvement in the safety, efficacy and quality profile of novel and complex biotherapeutics.
Partner With Us
If you have any R&D challenge of complex biotherapeutics, we would like to hear from you!
Please contact us at BD@vibrantx.io.
Topnotched Management
Dr. Larry Wang
CEO
Dr. Oliver Zhang
SVP, Antibody Discovery
Dr. Liang Deng
SVP, CMCBeing aware of the obstacles and hardships on the way to unfolding the relationships among proteins sequences, 3D structures and therapeutic functions, Vibrant Therapeutics has undoubtedly brought scientists much closer to achieving the ultimate goal of building broader knowledge and deeper understanding of structural biology, and by that, the revolutionary bionovels to tackle unmet medical needs can eventually be designed.
Larry Wang, Ph.D.
CEO & FounderVibrant AI drug discovery platform can not only provide effective solutions to bionovels design in early drug discovery, but also take the late stage druggability and manufacturability factors into consideration.
Liang Deng, Ph.D.
SVP, CMCVibrantFold is able to predict tremendous amount of novel and complex bionovels structures in minutes with remarkable accuracy. With the empowerment of AI generative model, we can now generate a gigantic virtual antibody mutant library in silico, which contains innumerable antibody structures, and this virtual library size can be scaled up almost infinitely.
Oliver Zhang, Ph.D.
SVP, Antibody Discovery & Co-FounderTimeline
Join Us
You'll be surprised how extraordinary you truly are. Explore your future here!